HomeCompareCTBO vs PLD

CTBO vs PLD: Dividend Comparison 2026

CTBO yields 198.02% · PLD yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CTBO wins by $106.19M in total portfolio value
10 years
CTBO
CTBO
● Live price
198.02%
Share price
$1.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$112.70M
Annual income
$56,534,499.65
Full CTBO calculator →
PLD
PLD
● Live price
3.18%
Share price
$128.78
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.50M
Annual income
$5,256,436.18
Full PLD calculator →

Portfolio growth — CTBO vs PLD

📍 CTBO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCTBOPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CTBO + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CTBO pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CTBO
Annual income on $10K today (after 15% tax)
$16,831.68/yr
After 10yr DRIP, annual income (after tax)
$48,054,324.70/yr
PLD
Annual income on $10K today (after 15% tax)
$270.62/yr
After 10yr DRIP, annual income (after tax)
$4,467,970.75/yr
At 15% tax rate, CTBO beats the other by $43,586,353.95/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CTBO + PLD for your $10,000?

CTBO: 50%PLD: 50%
100% PLD50/50100% CTBO
Portfolio after 10yr
$59.60M
Annual income
$30,895,467.91/yr
Blended yield
51.84%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

CTBO
No analyst data
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+5.6% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CTBO buys
0
PLD buys
0
No recent congressional trades found for CTBO or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCTBOPLD
Forward yield198.02%3.18%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$112.70M$6.50M
Annual income after 10y$56,534,499.65$5,256,436.18
Total dividends collected$106.15M$6.37M
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: CTBO vs PLD ($10,000, DRIP)

YearCTBO PortfolioCTBO Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$30,502$19,801.98$11,255$555.24+$19.2KCTBO
2$89,086$56,448.56$13,062$1,018.59+$76.0KCTBO
3$249,403$154,080.96$15,903$1,926.67+$233.5KCTBO
4$670,003$403,142.26$20,839$3,823.32+$649.2KCTBO
5$1,729,066$1,012,162.66$30,464$8,166.08+$1.70MCTBO
6$4,291,289$2,441,188.37$52,054$19,457.30+$4.24MCTBO
7$10,253,990$5,662,310.92$109,886$54,188.93+$10.14MCTBO
8$23,616,660$12,644,890.45$304,030$186,451.18+$23.31MCTBO
9$52,487,868$27,218,041.68$1,166,125$840,813.32+$51.32MCTBO
10$112,696,518$56,534,499.65$6,504,190$5,256,436.18+$106.19MCTBO

CTBO vs PLD: Complete Analysis 2026

CTBOStock

Cantabio Pharmaceuticals, Inc., a preclinical stage biotechnology company, focuses on the research, development, and commercialization of novel therapies for Parkinson's disease (PD), Alzheimer's disease (AD), and other related diseases. Its lead programs include CB101, a DJ-1 targeting small molecule pharmacological chaperone for use in the treatment of PD; CB201, a CNS penetrant engineered DJ-1 protein for use in the treatment of PD; CB301, a Tau protein targeting small molecule pharmacological chaperone for use in the treatment of AD; and CB401, an Aß targeting small molecule pharmacological chaperone for use in the treatment of AD. The company has a collaboration agreement with Luxembourg Institute of Health to research the therapeutic targeting of the DJ-1 - protein to treat immune associated diseases. The company was founded in 2009 and is based in Palo Alto, California.

Full CTBO Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this CTBO vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CTBO vs SCHDCTBO vs JEPICTBO vs OCTBO vs KOCTBO vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.